Add thelocalreport.in As A Trusted Source
Less than one in ten people who could benefit from weight loss drugs access them due to high Drug cost and supply issuesThe World Health Organization (WHO) has warned.
there are more than a billion people living together around the world obesity And WHO has called for fair access GLP-1 drug Such as veggies, before this Guidance on drugs.
If action is not taken, the number of obese people is projected to double by 2030, stressing the body.
In September 2025, GLP-1 agonists – a type of drug that helps lower blood sugar levels by slowing digestion Eat and may reduce appetite – was added to the list of “essential” medications for the management of type 2 diabetes in high-risk groups.
But the new guidelines also suggest that these drugs should be used long-term to support people with obesity in addition to a healthy diet and regular exercise.
“Obesity is a major global health challenge that WHO is committed to addressing by supporting countries and people around the world to control it effectively and equitably,” said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General.
“Our new guidance recognizes that obesity is a chronic disease that can be treated with comprehensive and lifelong care.”
“Although medicine alone will not solve this global health crisis, GLP-1 therapy could help millions of people overcome obesity and reduce the harms associated with it,” he said.
Obesity is a complex, chronic disease and a major factor in cardiovascular disease, type 2 diabetes, and some types of cancer. It also contributes to poor outcomes for patients who have infectious diseases.
In addition to its health impacts, the global economic cost of obesity is projected to reach US$3 trillion annually by 2030.
The guideline may help in efforts to reduce the skyrocketing health costs associated with managing the condition and related health complications.
According to WHO, high costs, manufacturing and supply-chain barriers are universal barriers preventing people from accessing weight-loss medications.
Price of the drug Monzaro in UK increased It was increased by 170 percent to bring it in line with higher prices in other countries.
Despite rapid expansion in production, less than 10 percent of GLP-1 drugs are projected to reach those in need by 2030.
The guidelines call on countries and companies to help expand access to weight loss remedies through strategies such as tiered pricing and voluntary licensing – where a drug company allows others to make affordable off-brand versions of its patented drug.
Global demand for GLP-1 drugs has fueled the sale of counterfeit and substandard products, threatening patient safety, WHO has also warned. It emphasized regulated dispensing, prescription by qualified health care providers, patient education would help protect patient health.